Latest Period
Q1 2026
Security Snapshot
ADAPTIMMUNE THERAPEUTICS PLC - American Depositary Shares, each representing 6 Ordinary Shares (ADAPY) Institutional Ownership
CUSIP: 00653A107
13F Institutional Holders and Ownership History from Q2 2015 to Q1 2026
Institutions Reporting
1
Shares (Excl. Options)
3,661
Price
$0.02
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / American Depositary Shares, each representing 6 Ordinary Shares
- Symbol
- ADAPY
- Shares outstanding
- 1,571,428,571
- Reported price per share
- $0.02
- Price from insider filings
- $0.02
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 3,661
- Total reported value
- $72
- Share change
- -1,607,791
- Value change
- -$41,802
- Number of holders
- 1
Security identity
Issuer context
Latest holder snapshot
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- ADAPY - ADAPTIMMUNE THERAPEUTICS PLC - American Depositary Shares, each representing 6 Ordinary Shares is tracked under CUSIP 00653A107.
- 1 institution reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 6 to 1 between Q4 2025 and Q1 2026.
- Reported value moved from $41,897 to $72.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 1 institution filings for Q1 2026.
Security key
00653A107
Latest holder period
Q1 2026
13F holders
1
13D/G owners
3
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00653A107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
ADAPY
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO | 4.6% | $19,146,934 | 70,914,570 | BAILLIE GIFFORD & CO | 31 Dec 2024 | |||
| EcoR1 Capital, LLC | 4.2% | $6,600,000 | 66,000,000 | EcoR1 Capital, LLC | 15 Aug 2025 | |||
| New Enterprise Associates 14, L.P. | 0% | $0.4 | 4 | New Enterprise Associates 14, L.P. | 15 Aug 2025 |
As of 31 Mar 2026, 1 institutional investors reported holding 3,661 shares of ADAPTIMMUNE THERAPEUTICS PLC - American Depositary Shares, each representing 6 Ordinary Shares (ADAPY). This represents 0% of the company’s total 1,571,428,571 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
44
Latest
Q1 2026
Rows shown
1-25 of 44
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 3,661 | $72 | -$41,802 | $0.02 | 1 |
| 2025 Q4 | 1,611,452 | $41,897 | -$5,283,488 | $0.03 | 6 |
| 2025 Q3 | 42,101,464 | $5,465,824 | -$18,296,183 | $0.13 | 54 |
| 2025 Q2 | 115,567,681 | $27,687,316 | -$90,777 | $0.24 | 62 |
| 2025 Q1 | 116,071,575 | $22,853,519 | -$8,159,230 | $0.20 | 66 |
| 2024 Q4 | 124,428,941 | $67,025,039 | -$30,501,887 | $0.54 | 79 |
| 2024 Q3 | 151,690,402 | $144,141,106 | -$2,309,667 | $0.95 | 79 |
| 2024 Q2 | 153,890,194 | $150,022,429 | -$8,879,193 | $0.97 | 75 |
| 2024 Q1 | 162,072,769 | $256,066,400 | +$30,563,845 | $1.58 | 77 |
| 2023 Q4 | 143,571,040 | $113,849,906 | -$3,752,852 | $0.79 | 76 |
| 2023 Q3 | 148,301,336 | $115,679,142 | +$2,660,882 | $0.78 | 77 |
| 2023 Q2 | 144,690,313 | $133,837,483 | +$26,555,200 | $0.92 | 85 |
| 2023 Q1 | 115,955,853 | $126,383,143 | +$2,091,094 | $1.09 | 62 |
| 2022 Q4 | 113,878,984 | $166,253,761 | +$537,924 | $1.46 | 64 |
| 2022 Q3 | 113,851,192 | $122,380,454 | -$1,743,981 | $1.08 | 60 |
| 2022 Q2 | 114,736,783 | $195,049,662 | +$7,481,032 | $1.70 | 71 |
| 2022 Q1 | 108,766,325 | $224,054,046 | -$22,141,212 | $2.06 | 74 |
| 2021 Q4 | 113,574,015 | $425,913,139 | -$9,027,809 | $3.75 | 81 |
| 2021 Q3 | 111,668,173 | $577,323,373 | +$3,505,834 | $5.17 | 91 |
| 2021 Q2 | 111,675,475 | $475,734,700 | -$26,231,441 | $4.26 | 80 |
| 2021 Q1 | 117,483,515 | $623,821,340 | -$3,868,785 | $5.31 | 80 |
| 2020 Q4 | 118,175,702 | $636,961,652 | -$92,063,137 | $5.39 | 86 |
| 2020 Q3 | 129,788,880 | $1,035,562,966 | +$4,544,653 | $7.98 | 75 |
| 2020 Q2 | 128,234,852 | $1,283,635,211 | +$368,627,077 | $10.01 | 75 |
| 2020 Q1 | 93,844,355 | $255,255,329 | +$79,458,201 | $2.72 | 45 |